Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: Effects of in vivo statin treatment

Annals of the Rheumatic Diseases

Volumn 74, Issue 7, 2015, Pages 1450-1458

  Ruiz Limon, Patricia ^a   Barbarroja, Nuria ^a   Perez Sanchez, Carlos ^a   Aguirre, Maria Angeles ^a   Bertolaccini, Maria Laura ^b   Khamashta, Munther A ^b   Rodriguez Ariza, Antonio ^a   Almadén, Yolanda ^c   Segui, Pedro ^a   Khraiwesh, Husam ^d   Gonzalez Reyes, Jose Antonio ^d   Villalba, Jose Manuel ^d   Collantes Estevez, Eduardo ^a   Cuadrado, Maria Jose ^b   Lopez Pedrera, Chary ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; LIPID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNITY; BIOGENESIS; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ELECTRON MICROSCOPY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPID METABOLISM; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MONOCYTE; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT DURATION; VASCULITIS; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; CELL CULTURE; COMORBIDITY; COMPLICATION; DRUG EFFECTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; OXIDATION REDUCTION REACTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADULT; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CELLS, CULTURED; COMORBIDITY; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IN VITRO TECHNIQUES; INDOLES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MONOCYTES; OXIDATION-REDUCTION; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84934963422     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204351     Document Type: Article

References (38)

1. López-Pedrera C, Aguirre MA, Barbarroja N, et al. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol 2010;2010;pii: 607084.
2. Full LE, Ruisanchez C, Monaco C. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid artritis and systemic lupus erythematosus. Arthritis Res Ther 2009;11:217-26.
3. Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with systemic lupus erythematosus. Mechanisms and management. Nat Rev Rheumatol 2012;8:214-23.
4. Pengo V, Bison E, Ruffatti A, et al. Autoantibodies to oxidized LDL/β2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism. Thromb Res 2008;122:556-9.
5. Firuzi O, Fuksa L, Spadaro C, et al. Oxidative stress parameters in different systemic rheumatic diseases. J Pharm Pharmacol, 2006;58:951-7.
6. Gratchev A, Sobenin I, Orekhov A, et al. Monocytes as a diagnostic marker of cardiovascular diseases. Immunobiology 2012;217:476-82.
7. Orme J, Mohan CH. Macrophages and neutrophils in systemic lupus erythematosus - an online molecular catalog. Autoimmun Rev 2012;11:365-72.
8. Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 2007;99:732-8.
9. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-83.
10. Waehre T, Yndestad A, Smith C, et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 2004;109:1966-72.
11. López-Pedrera C, Ruiz-Limón P, Aguirre MA, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis 2011;70:675-82.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
13. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
14. López-Pedrera C, Buendía P, Cuadrado MJ, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006;54:301-11.
15. López-Pedrera C, Aguirre MA, Buendía P, et al. Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. Arthritis Rheum 2010;62:869-77.
16. Cuadrado MJ, Buendía P, Velasco F, et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 2006;4:2461-9.
17. Ames PRJ, Antionolfi I, Scenna G, et al. Atherosclerosis in thrombotic primary antiphospholipid syndrome. J Thromb Haemost 2009;7:537-42.
18. th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007;23:75-80.
19. Sato T. A modified method for lead staining of thin sections. J Electron Microsc 1968;17:158-9.
20. Weibel ER. Stereological methods. Practical methods for biological morphometry. Vol 1. New York: Academic Press, 1979.
21. Weibel ER, Bolender RP. Stereological techniques for electron microscopic morphometry. In: Hayat MAŽ. ed Principles and techniques of electron microscopy. Vol 3. New York: Van Nostrand Rheinhold Company, 1973:26-46.
22. Legein B, Temmerman L, Biessen EA, et al. Inflammation and immune system interactions in atherosclerosis. Cell Mol Life Sci 2013;70:237-96.
23. Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol 2011;7:691-9.
24. Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011;187:538-52.
25. Motoki Y, Nojima J, Yanagihara M. Anti-phospholipid antibodies contribute to arteriosclerosis in patients with systemic lupus erythematosus through induction of tissue factor expression and cytokine production from peripheral blood mononuclear cells. Thromb Res 2012;130:667-73.
26. Perazzio SF, Salomão R, Silva NP, et al. Increased neutrophil oxidative burst metabolism in systemic lupus erythematosus. Lupus 2012;21:1543-51.
27. Oka T, Hikoso S, Yamaguchi O, et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012;485:251-5.
28. Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, et al. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment. Blood 2012;119:5859-70.
29. Yəlmaz S, Caliskan M, Kulaksəzoglu S, et al. Association between serum total antioxidant status and coronary microvascular functions in patients with SLE. Echocardiography 2012. doi:10.1111/j.1540-8175.2012.01797.x
30. Amuro H, Ito T, Miyamoto R, et al. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. Arthritis Rheum 2010;62:2073-85.
31. Mok CC, Wong CK, To CH, et al. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res 2011;63:875-83.
32. Petri MA, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011;70:760-5.
33. Tokunaga F, Nakagawa T, Nakahara M, et al. SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex. Nature 2011;471:633-6.
34. Lin CW, Hsieh YS, Hsin CH, et al. Effects of NFKB1 and NFKBIA gene polymorphisms on susceptibility to environmental factors and the clinicopathologic development of oral cancer. PLoS ONE 2012;7:e35078.
35. Feng W, Xing D, Hua P, et al. The transcription factor ETS-1 mediates proinflammatory responses and neointima formation in carotid artery endoluminal vascular injury. Hypertension 2010;55:1381-8.
36. Antonopoulos AS, Margaritis M, Shirodaria C, et al. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Thromb Haemost 2012;108:840-8.
37. Mensink M, Hesselink MK, Russell AP, et al. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. Int J Obes 2007;31:1302-10.
38. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;127:1109-22.